Drawing for RIGEL ONE CARE

USPTO serial 87817100

RIGEL ONE CARE

Reviewed by CopyMark Law Group

Reg. 6102551Status 702Renewal
Filing date
Status date
Registration date
Jul 14, 2020
Examiner
CAHILL, CLARE GALLAGHER
Law office
Historical data usage

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 702: Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use.

Need help with RIGEL ONE CARE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,097*

Plus Government fees of $1,275

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Jamed J. Saul

Jamed J. Saul FAEGRE DRINKER BIDDLE & REATH LLP320 South Canal Street, Suite 3300Chicago, IL 60606United States

Goods and services

ClassDescriptionStatusFirst use
035Providing a database for collecting and reporting information pertaining to medical treatment, insurance, and prescription drug dispensing and management for business purposes; Business administration of a patient support program, which helps patients, in coordination with their healthcare provider, access, start, and comply with therapy as prescribed, and provides co-pay assistance, assistance with insurance and healthcare providers, coverage and reimbursement information, general education and support, and information about products, health topics, and related resources; Providing business information and billing services in the field of healthcare, namely, providing reimbursement information, drug pricing, payment tracking, co-payment data and other market intelligence to health care providers, insurers and consumers; Providing consumer product information relating to prescription drugs to distributors, pharmacies and consumers; Distribution of product advertising materials for sales representatives of prescription drugs; Assisting patients in enrolling in pharmaceutical reimbursement programs of others; Providing a website featuring information for medical professionals, pharmacies, insurance companies and drug distributors regarding retail pharmacy business information about the administration and dosing of pharmaceuticals; Medical billing support services, namely, providing an internet website portal featuring billing information to healthcare professionals, patients and patient caregivers relating to reimbursement for pharmaceutical preparations, health care and prescription drugsACTIVE—
036Advisory services and consultancy regarding healthcare benefits and pharmacy benefits; providing information and guidance in connection with health, medical, and pharmacy insurance benefit plans; insurance consultation services, namely, assisting physician offices and patients to identify the scope of coverage offered by patient medical and pharmaceutical insurance; insurance consultation services, namely, assisting physician offices and patients to obtain prior authorization for medical and pharmaceutical insurance claims and the preparation and submission of related paperwork and assisting physician offices and patients to appeal denial of medical and pharmaceutical insurance claims and the preparation and submission of related paperwork; Financial information, namely, providing reimbursement information, drug pricing, payment tracking, and co-payment information to health care providers, insurers and consumers; Financial administration of health reimbursement arrangements, namely, providing an internet website portal featuring financial information to healthcare professionals, patients and patient caregivers relating to reimbursement for pharmaceutical preparations, health care and prescription drugsACTIVE—
044Medical information services; Medical informational services, namely, providing information regarding prescription drugs for drug distributors, insurance companies, pharmacies and medical professionals; Providing a website featuring information for medical professionals, pharmacies, insurance companies and drug distributors regarding therapeutic properties of pharmaceuticals, the treatment of diseases and medical conditions, and medical information about the administration and dosing of pharmaceuticals; Patient support services relating to treatment of medical disorders, namely, providing information relating to therapeutic properties of pharmaceuticals, the treatment of diseases and medical conditions, medical information about the administration and dosing of pharmaceuticals; Providing a website featuring healthcare information, namely, providing resources in the field of pharmaceuticals for treatment of diseases and links to such resources; Medical information services, namely, providing a website in the medical, pharmaceutical and health fields featuring information related to health, wellness, healthcare, patient support services, pharmaceuticals, pharmaceutical access, drug safety and/or drug compatibility in relation to therapy and treatment of individuals, adherence to pharmaceutical protocols, and the diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical care consulting services in the fields of patient treatment and treatment protocolsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jan 14, 2026NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Jan 14, 2026C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Jan 12, 2026APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Oct 8, 2025E815TEAS SECTION 8 & 15 RECEIVED—
Jul 14, 2025REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Feb 3, 2023CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Feb 3, 2023TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Feb 3, 2023ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 3, 2023REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Feb 3, 2023COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
May 25, 2021CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
May 25, 2021TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
May 25, 2021ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 25, 2021REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
May 25, 2021COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Jul 14, 2020R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jun 12, 2020SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Jun 11, 2020CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
May 19, 2020SUPCSTATEMENT OF USE PROCESSING COMPLETE—
May 19, 2020AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
May 4, 2020IUAFUSE AMENDMENT FILED—
May 4, 2020EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Nov 12, 2019NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Sep 17, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 17, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 28, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Aug 9, 2019ALIEASSIGNED TO LIE—
Jul 31, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 30, 2019TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 29, 2019CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 29, 2019ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
May 13, 2019TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jan 29, 2019GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Jan 29, 2019GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jan 29, 2019CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Dec 22, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 20, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 20, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 20, 2018GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 20, 2018GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 20, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 12, 2018DOCKASSIGNED TO EXAMINER—
Mar 8, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 5, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance